Category: Respiratory

Theravance COPD drug clears safety study, setting up NDA

Theravance Biopharma and Mylan are still on course to file for approval of their nebulized chronic obstructive pulmonary disease (COPD) therapy in the fourth quarter after posting 12-month safety data. The trial suggests revefenacin has a tolerable safety profile comparable to that of Boehringer Ingelheim’s bronchodilator Spiriva. http://www.fiercebiotech.com/biotech/theravance-copd-drug-clears-safety-study-setting-up-nda

NICE recommends AstraZeneca lung treatment

AstraZeneca’s Daxas (roflumilast) has received recommendation from NICE for the treatment of chronic obstructive pulmonary disease (COPD) is has emerged, meaning the therapy could soon be available for routine use on the NHS. The assessment covers adults whose severe COPD has not responded to other treatments.
read more http://www.pharmafile.com/news/514510/nice-recommends-astrazeneca-lung-treatment

GOLD guidelines for the management of COPD – 2017 update

Chronic obstructive lung disease (COPD) is the third leading cause of death in the United States1 and a major cause of mortality and morbidity around the world. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released a new “2017 Report”2 with modified recommendations for the diagnosis, management, and prevention of COPD. The report contains […] http://www.pm360online.com/gold-guidelines-for-the-management-of-copd-2017-update/